BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

Christian R. Schubert, Patricio O'Donnell, Jie Quan, Jens R. Wendland, Hualin S. Xi, Ashley R. Winslow, Enrico Domenici, Laurent Essioux, Tony Kam-Thong, David C. Airey, John N. Calley, David A. Collier, Hong Wang, Brian Eastwood, Philip Ebert, Yushi Liu, Laura Nisenbaum, Cara Ruble, James Scherschel, Ryan Matthew SmithHui Rong Qian, Kalpana Merchant, Michael Didriksen, Mitsuyuki Matsumoto, Takeshi Saito, Nicholas J. Brandon, Alan J. Cross, Qi Wang, Husseini Manji, Hartmuth Kolb, Maura Furey, Wayne C. Drevets, Joo Heon Shin, Andrew Jaffe, Yankai Jia, Richard E. Straub, Amy Deep-Soboslay, Thomas Hyde, Joel E. Kleinman, Daniel R. Weinberger

Research output: Contribution to journalShort surveypeer-review

43 Scopus citations


We outline an ambitious project to characterize the genetic and epigenetic regulation of multiple facets of transcription in distinct brain regions across the human lifespan in samples of major neuropsychiatric disorders and controls. Initially focused on schizophrenia and mood disorders, the goal of this consortium is to elucidate the underlying molecular mechanisms of genetic associations with the goal of identifying novel therapeutic targets. The consortium currently consists of seven pharmaceutical companies and a not-for-profit medical research institution working as a precompetitive team to generate and analyze publicly available archival brain genomic data related to neuropsychiatric illness.

Original languageEnglish (US)
Pages (from-to)1078-1083
Number of pages6
Issue number6
StatePublished - 2015

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders'. Together they form a unique fingerprint.

Cite this